Evidence map›Paper›PMID 38847160›Full record

ReviewCurrent pharmaceutical biotechnology2025

Artificial Intelligence in Cancer Diagnosis: A Game-changer in Healthcare.

Pramit Sahoo, Meghoparna Kundu, Jeenatara Begum

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Molecular Targets for Intracranial Aneurysm Treatment.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pramit SahooGuru Nanak Institute of Pharmaceutical Science and Technology (An Autonomous Institution under MAKAUT), 157/F Nilgunj Road, Panihati, Kolkata, 700114, India.ORCID 0009-0009-5301-264X
Meghoparna KunduGuru Nanak Institute of Pharmaceutical Science and Technology (An Autonomous Institution under MAKAUT), 157/F Nilgunj Road, Panihati, Kolkata, 700114, India.ORCID 0009-0002-6524-6311
Jeenatara BegumGuru Nanak Institute of Pharmaceutical Science and Technology (An Autonomous Institution under MAKAUT), 157/F Nilgunj Road, Panihati, Kolkata, 700114, India.ORCID 0000-0001-8391-4147

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early cancer identification is essential for increasing survival rates and lowering the disease's burden in today's society. Artificial intelligence (AI)-based algorithms may help in the early detection of cancer and resolve problems with current diagnostic methods. This article gives an overview of the prospective uses of AI in early cancer detection. The authors go over the possible applications of Artificial Intelligence algorithms used for screening risk of malignancy in asymptomatic patients, investigating as well as prioritising symptomatic individuals, and more accurately diagnosing cancer recurrence. In screening programmes, the importance of patient selection and risk stratification is emphasised, and AI may be able to assist in identifying people who are most at risk of acquiring cancer. Aside from pathology slide and peripheral blood analysis, AI can also increase the diagnostic precision of imaging methods like computed tomography (CT) and mammography. A summary of various AI techniques is given in the review, covering more sophisticated deep learning and neural networks and more traditional models like logistic regression. The advantages of deep learning algorithms in spotting intricate patterns in huge datasets and their potential to increase the precision of cancer diagnosis are emphasised by the authors. The ethical concerns surrounding the application of AI in healthcare are also discussed, and include topics like prejudice, data security, and privacy. A review of the models now employed in clinical practice is included along with a discussion of the prospective clinical implications of AI algorithms. Examined are AI's drawbacks and hazards, such as resource requirements, data quality, and the necessity for consistent reporting. In conclusion, this study emphasises the utility of AI algorithms in the early detection of cancer and gives a general overview of the many strategies and difficulties involved in putting them into use in clinical settings.

Indexed as

Artificial IntelligenceEarly Detection of CancerNeoplasmsAlgorithmsDelivery of Health CareHumansartificial intelligenceCancerdeep learning.early diagnosismachine learningscreening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.